Clinical trial · Interventional
Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
Dose-Modified Oral Combination Chemotherapy In Patients With Aids-Related Non-Hodgkin's Lymphoma In The United States And Africa
NCT00049439CI-TRIAL-00003558completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining lomustine, etoposide, cyclophosphamide, and procarbazine in treating patients who have AIDS-related non-Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| filgrastim | Biological | Filgrastim | ALIAS |
| lomustine | Drug | Lomustine | ALIAS |
| procarbazine hydrochloride | Drug | Procarbazine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Disease response
- timeFrame
- Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
Secondary outcomes (1)
- measure
- Quality of life as assessed by the Functional Living Index-Cancer and the Brief Symptom Inventory
- timeFrame
- days 1 and 2 of courses 1 and 2 and on day 84
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of acquired immune deficiency syndrome * Histologically confirmed stage I, II, III, or IV intermediate- or high-grade non-Hodgkin's lymphoma * B-cell, T-cell, or indeterminate immunologic phenotype * Measurable or evaluable disease * No clinical, radiographic, or cytological evidence of CNS parenchymal, vitreal, or leptomeningeal involvement by lymphoma NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age * 18 and over (in the United States) * 16 and over (in Africa) Performance status * ECOG 0-3 Life expectancy * At least 6 weeks Hematopoietic * WBC at least 1,500/mm3 * Platelet count at least 50,000/mm3 Hepatic * Bilirubin no greater than 3.0 mg/dL Renal * Creatinine no greater than 3.0 mg/dL Other * Concurrent active infection for which patient is receiving treatment allowed provided clinical status is stable * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior chemotherapy for lymphoma Endocrine therapy * Not specified Radiotherapy * Prior radiotherapy for stage I or II disease allowed provided there is documentation of disease progression Surgery * Not specified Other * Concurrent antiretroviral therapy (except zidovudine) allowed
References
Publications (0)
Data not yet available
No reference posted for this study.